Navigation Links
Egalet Appoints Stan Musial as CFO

MALVERN, Pa., May 8, 2013 /PRNewswire/ -- Egalet Ltd., a privately held specialty pharmaceutical company focused on developing safe, effective and abuse-deterrent medications, announced today the appointment of Stan Musial as chief financial officer (CFO). 

"The addition of Stan to the management team comes at a critical time as the most advanced products in Egalet's pipeline of abuse-deterrent opioids are nearing phase 3," said Bob Radie , president and CEO.  "Stan's finance experience will be invaluable as we move our pipeline through development and ultimately to the commercial market."

Stan has held senior financial management positions for both publicly-held and privately-held companies, becoming experienced in executing growth strategies, raising capital, and mergers and acquisitions.  Stan most recently spent six years as vice president of finance and administration, chief financial officer, treasurer and secretary of Prism Pharmaceuticals, a specialty pharmaceutical company, which was successfully sold to Baxter Healthcare in 2011.  Prior to joining Prism he held the position of vice president, finance, and CFO for Strategic Diagnostics, Inc. (SDIX), a publicly-held biotechnology company.  He began his career with KPMG LLP.  Stan holds an MBA in finance from Temple University and a B.S. degree in accounting from Pennsylvania State University and is a Certified Public Accountant.

"I am excited to join Egalet—a company seeking to advance its pipeline of abuse deterrent opioids by taking advantage of the expedited 505(b)(2) regulatory pathway to address the growing need for safe pain medicines," said Stan Musial

About Egalet Ltd.
Egalet Ltd. is a European-based specialty pharmaceutical company using its patented technology to produce novel therapeutics on its own and with partners.  Based on the proprietary technology, Egalet is developing a pipeline of abuse-deterrent opioids that are nearing pivotal testing.  In addition, Egalet has collaborations with pharmaceutical and biotechnology companies in the initial phase of clinical testing. 

Egalet has pioneered one of the world's first erosion-based delivery technologies to enable the controlled release of drugs through gradual erosion of a tablet.   In addition, the Egalet® technology, a novel, patented drug delivery platform, is designed to prevent easy extraction and to deter the abuse of medications via known routes of abuse, including chewing, snorting, and injecting.  The uniquely shaped, patient-friendly tablet consists of matrix and can add a shell or coat.  By altering the composition of the shell and matrix, a variety of extended-release formulations can be produced.  The technology offers a predictable and tailored pharmacokinetic profile, lacks a significant food effect and alcohol dose dumping, and can be used with a broad range of opioids and non-opioids.  Egalet has an extensive portfolio of both filed patents and patent applications to protect its inventions covering both the platform technology and specific products.  Please visit for more information.

E. Blair Schoeb 
Tel.: 917-432-9275

SOURCE Egalet Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Egalet to Present at Life Sciences Europe Conference
2. Egalet Announces Issuance of U.S. Patent
3. CLAAD Selects Egalet As Top Five Technologies To Reduce Prescription Drug Abuse Honoree
4. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
5. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
6. Nephros Appoints John C. Houghton as President and Chief Executive Officer
7. Elsevier Appoints New President of Elsevier CPM Resource Center
8. GenWay Biotech Appoints New Vice President of Custom/OEM
9. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
10. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
11. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
Post Your Comments:
(Date:12/1/2015)... -- ) has announced ... Market 2015 - Forecast to 2020" report ... has announced the addition of the "Drug ... report to their offering. --> ... the addition of the "Drug Delivery Technology ...
(Date:12/1/2015)... Sweden , December 1, 2015 ... Cancer Study Group (IBCSG, Bern ) and ... to be part of a state of the art trial, ... --> --> The study, ... treated with anti-hormonal therapy in combination with palbociclib, a cancer ...
(Date:11/30/2015)... BASEL, Switzerland , Dec. 1, 2015 /PRNewswire/ ... its wholly-owned UK subsidiary Proximagen Ltd., today announced a ... oral small molecule inhibitor of Vascular Adhesion Protein 1 ... the treatment of inflammatory disease. The VAP-1 inhibitor is ... --> --> Under the terms of ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... For the ... is why Hollister Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic ... the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice President North America. ...
(Date:12/1/2015)... ... ... McLean, VA., December 1, 2015 - Octo Consulting Group, ... development contract to support the National Geospatial-Intelligence Agency's (NGA) IT Services Directorate. ... as well as operations and sustainment support to the NGA’s Agile Web Presence ...
(Date:12/1/2015)... ... ... XTC Semifinals 2016 - CES, Las Vegas, Nevada - Extreme ... 2016, the world’s largest Consumer Electronic Show, where they will present to a panel ... Pacific Investments Veronica Serra, and venture capitalist Tim Draper among many other top names ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Arash ... Modern Man for 2015. , Angeleno Magazine is a division of Modern ... in 1994, Modern Luxury includes more than 50 magazine titles across 15 major ...
(Date:11/30/2015)... ... 2015 , ... Olympic Gold Medalists and Celebrity Moms Dara ... various categories through traditional and social media marketing campaigns and other branding initiatives. ... Medal Moms who can connect with today’s most important consumer: mothers. In addition ...
Breaking Medicine News(10 mins):